KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer
Authors
Sands, J.Reck, M.
Navarro, A.
Chiang, A. C.
Lu, S.
Peled, N.
Paz-Ares, L. G.
Kerr, S. J.
Takahashi, T.
Smolin, A.
Chen, X. Q.
Zhao, B.
El-Osta, H. E.
Califano, Raffaele
Affiliation
Dana-Farber Cancer Institute, Boston, MAIssue Date
2022
Metadata
Show full item recordCitation
Sands J, Reck M, Navarro A, Chiang AC, Lu S, Peled N, et al. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305119.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS8606Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS8606